Windward Bio: Valuation, Funding & Investors
Windward Bio is a clinical-stage drug development company based in Switzerland, focused on improving outcomes for individuals with advanced immunological diseases, particularly severe respiratory conditions. The company is developing a novel long-acting monoclonal antibody targeting the TSLP ligand and is building a discovery pipeline of long-acting bispecifics to address high unmet medical needs and reduce treatment burdens globally.
Leadership & Board
- Current Number of Employees
- 50
- Current LinkedIn Followers
- 4,554
Latest Estimated Valuation
- Total Amount Raised
- $200M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $200M
- Latest Funding Round
- Series A
Employee Trend
Windward Bio had 50 employees as of October 26, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
Windward Bio had 4,554 followers as of October 26, 2026. The number of followers increased by 33 (0.73%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Jan 10, 2025 | Series A | $200.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Novo Holdings | Series A |
Similar Companies
A snapshot of private companies similar to Windward Bio, helping you discover and navigate related company profiles.
Related News and Analysis
